Review and comparison of the long acting methylphenidate preparations

Psychiatric Quarterly

Volumn 76, Issue 3, 2005, Pages 259-269

  Liu, Feng ^a   Muniz, Rafael ^b   Minami, Haruka ^a   Silva, Raul R ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Attention deficit hyperactivity disorder; Long acting methylphenidate; Pharmacodynamic studies; Pharmacokinetic studies

Indexed keywords

LONG ACTING DRUG; METHYLPHENIDATE;

AREA UNDER THE CURVE; ATTENTION DEFICIT DISORDER; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG FORMULATION; DRUG SOLUBILITY; GASTROINTESTINAL TRACT; HUMAN; REVIEW; TABLET FORMULATION; TECHNOLOGY; TREATMENT OUTCOME;

CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CLINICAL TRIALS; DECISION MAKING; DELAYED-ACTION PREPARATIONS; HUMANS; METHYLPHENIDATE; PHARMACEUTICAL PREPARATIONS;

EID: 21544445877     PISSN: 00332720     EISSN: 15736709     Source Type: Journal    
DOI: 10.1007/s11126-005-2979-0     Document Type: Review

References (31)

1. Cantwell DP: Attention deficit disorder: A review of the past 10 years. J Am Acad Child Adolesc Psychiatry 35:978-987, 1996.
2. Dulcan M: work group on quality issues. Practice parameters for the assessment and treatment of children, adolescents, and adults with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry 36:85S-121S, 1997.
3. Swanson JM, Seargent JA, Taylor E, et al: Attention deficit disorder and hyperkinetic disorder. Lancet 351:429-433, 1998.
4. Mannuzza S, Klein RG, Bessler A, et al: Adult psychiatric status of hyperactive boys grown up. Am J Psychiatry 155:493-498, 1998.
5. Dulcan M. Using psychostimulants to treat behavior disorder of children and adolescents. J Child Adolesc Psychopharmacol 1:7-20, 1990.
6. Tannock R: Attention deficit hyperactivity disorder: Advances in cognitive, neurobiological, and genetic research. J Child Psychol Psychiatry 39:65-99, 1998.
7. Bradley C: The behavior of children receiving benzedrine. Am J Psychiatry 94:577-585, 1937.
8. Sprague RL. Sleator EK: Methylphenidate in hyperkinetic children: Differences in dose effects on learning and social behavior. Science. 198(4323):1274-1276, 1977 Dec 23.
9. Spencer T, Biederman J, Wilens T, et al: Harding M, O'Donnell D, Griffin S. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35(4):409-432, 1996.
10. Gillberg C, Melander H, von Knorring A, et al: Long-term central stimulant treatment of children with attention deficit hyperactivity disorder: A randomized double-blind placebo-controlled trial. Arch Gen Psychiatry 54:857-864, 1997.
11. Schachar R, Tannock R, Cunningham C, et al: Behavioral, situational, and temporal effects of treatment of ADHD with methylphenidate. J Am ACad Child Adolesc Psychiatry 36:754-763, 1997.
12. MTA Cooperative Group: A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Arch Gen Psychiatry 56:1073-1086, 1999a.
13. MTA Cooperative Group: Moderators and mediators of treatment response for children with ADHD: The MTA study. Arch Gen Psychiatry 56:1088-1096, 1999b.
14. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, et al: Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am ACad Child Adolesc Psychiatry 40:180-187, 2001.
15. Greenhill LL, Pliszka S, Dulcan MK: Work group of quality issues. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad child Adolesc Psychitry 41:26S-49S, 2002.
16. Pelham WE Jr, Sturges J, Hoza J, et al: Sustained release and standard methylphenidate effects on cognitive and social behavior in children with attention deficit disorder. Pediatrics 80:491-501, 1987.
17. Swanson J, Gupta S, Guinta D, et al: Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clin Pharmacol Ther 66:295-305, 1999.
18. Birmaher B, Greenhill LL, Cooper TB, et al: Sustained release methylphenidate: pharmacokinetic studies in ADDH males. J Am Acad Child Adolesc Psychiatry 28:768-772, 1989.
19. PDR Physicians Desk Reference, 58th ed. Montvale, New Jersey, Thompson, 2004.
20. Wolraich ML, Greenhill LL, Pelham W, et al: Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics. 108:883-892, 2001.
21. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, et al: Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6):E105, 2001.
22. Modi NB, Lindemulder B, Gupta SK: Single- and multiple-dose pharmacokinetic of an oral once-a-day osmotic controlled-release OROS (Methylphenidate HCl) formulation. J Clin Pharmacol. 40:379-88, 2000.
23. Auiler JF, LiuK, Lynch JM, et al: Effect of food on early drug exposure from extended-release stimulants: Results from Concerta, Adderall-XR food evaluation (CAFÉ) study. Curr Med REs Opin 18:311-318, 2002.
24. Gonzalez MA, Pentikis HS, Anderl N, et al: Methylphenidate bioavailability from two extended-release formulations. Int J Clin Pharmacol Ther 40(4):175-184, 2002.
25. Swanson JM, Wigal SB, Wigal T, et al: A comparison of once-daily extended- release methylphenidate formulations in children with attention-deficit/hyperactivity disorder in the laboratory school (the Comacs Study). Pediatrics 113(3 Pt 1):206-216, 2004.
26. Pentikis HS, Simmons RD, Benedict MF, et al: Methylphenidate bioavailability in adults when an extended-release multiparticulate formulation is administered sprinkled on food or as an intact capsule. J Am Acad Child Adolesc Psychiatry 41(4):443-449, 2002.
27. Markowitz JS, Straughn AB, Patrick KS, et al: Pharmacokinetics of methylphenidate after oral administration of two modified-release formulations in healthy adult volunteers. Clin Pharmacokinet 42(4):393-401, 2003.
28. Lopez F, Silva R, Pestreich L, et al: Comparative efficacy of two once daily methylphenidate formulations (Ritalin LA and Concerta) and placebo in children with attention deficit hyperactivity disorder across the school day. Pediatr drug 5(8):545-555, 2003.
29. Markowitz JS, Straughn AB, Patrick KS: Advances in the pharmacotherapy of attention-deficit hyperactivity disorder: Focus on methylphenidate formulations. Pharmacotherapy 23(10):1281-1299, 2003.
30. Silva RR, Brams M, Childress A, Lopez FA, Pestreich L, Muniz R: Efficacy of two once daily methylphenidate formulations in children with ADHD. Abstract Proceedings of New Research for the Annual Meeting of the American Psychiatric Association, New York, 344, 2004.
31. Lee L, Kepple J, Wang Y, et al: Bioavailability of modified-release methylphenidate: influence of high-fat breakfast when administered intact and when capsule content sprinkled on applesauce. Biopharm Drug Dispos 24:233-243, 2003.